Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis

NCT05123703 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05123703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05123703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 19, 2022
Completion date
September 17, 2029
Enrollment
188 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis